Treating Autism With Bumetanide: Are Large Multicentric and Monocentric Trials on Selected Populations Complementary?

Abstract

In their article in the Journal, Sprengers et al.1 conclude that bumetanide does not attenuate autism spectrum disorder (ASD) despite a nominally significant treatment effect in repetitive behaviors, which is a core symptom of ASD but was defined as a secondary measure in this trial. Four earlier studies performed by 3 independent institutes, including 2 studies2,3 not mentioned by Sprengers et al., testing a total of 169 children (versus 122 placebo) showed a significant amelioration of ASD symptoms. Bumetanide also significantly attenuated behavioral features of patients with tuberous sclerosis according to another study by Sprengers' same group.4.

• Authors: Eric Lemonnier, Hamed Rabiei, David Makowski, Nouchine Hadjikhani, Yehezkel Ben-Ari
• Journal: Journal of the American Academy of Child and Adolescent Psychiatry (J Am Acad Child Adolesc Psychiatry) Vol. 60 Issue 8 Pg. 937-938 (08 2021) ISSN: 1527-5418 [Electronic] United States
• PMID: 33385505 (Publication Type: Letter, Comment)
• Copyright: Copyright © 2021 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.

Chemical References

• Bumetanide

Topics

• Autism Spectrum Disorder (drug therapy)
• Autistic Disorder
• Bumetanide (pharmacology)
• Child
• Humans